GSK Jul 2024 41.000 put

OPR - OPR Delayed price. Currency in USD

Add to watchlist

1.6000

+0.7300

(+83.91%)

As of 12:59PM EDT. Market open.

Investing.com
Moderna shares decline, RSV vaccine efficacy lags behind competitors
Investing.com - Moderna Inc (NASDAQ:MRNA) experienced an 11% drop on Wednesday after the company disclosed that its respiratory syncytial virus (RSV) vaccine, mResvia, exhibited 50% efficacy in preventing the illness 18 months post-administration.
Business Wire
US FDA Approves Expanded Age Indication for GSK’s AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk
PHILADELPHIA, June 07, 2024--US FDA approves expanded age indication for GSK’s AREXVY, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk
Insider Monkey
The City With the highest HIV/AIDS Rates in the US
We recently compiled a list of 20 Cities With the Highest HIV/AIDS Rates in the US and in this article, we will talk about the city with the highest HIV/AIDS rates in the US. HIV Incidence and Prevalence in the United States The government of the United States has set a goal to reduce the […]